Drug Profile
Disitertide
Alternative Names: P-144; Peptide 144Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Digna Biotech; University of Navarra
- Developer Avadel Pharmaceuticals; Digna Biotech; ISDIN; University of Navarra
- Class Peptides
- Mechanism of Action Apoptosis stimulants; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Age-related macular degeneration; Corneal ulcer; Dry eyes; Systemic scleroderma
Highest Development Phases
- Phase II Systemic scleroderma
- No development reported Age-related macular degeneration; Corneal ulcer; Dry eyes; Pulmonary fibrosis
- Discontinued Actinic keratosis; Burns; Fibrosis; Glioblastoma; Keloids; Psoriasis; Skin cancer
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Glioblastoma in Spain (unspecified route)
- 28 May 2020 No recent reports of development identified for preclinical development in Glioblastoma in Spain
- 28 Oct 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Spain (Ophthalmic)